MRTX Mirati Therapeutics, Inc. Stock Quote

MRTX [NASD]

Index	-	P/E	-	EPS (ttm)	-11.90	Insider Own	0.80%	Shs Outstand	55.47M	Perf Week	1.88%
Market Cap	3.60B	Forward P/E	-	EPS next Y	-12.78	Insider Trans	-3.38%	Shs Float	52.20M	Perf Month	71.42%
Income	-634.50M	PEG	-	EPS next Q	-3.49	Inst Own	-	Short Float	9.03%	Perf Quarter	-19.32%
Sales	72.80M	P/S	49.50	EPS this Y	-40.90%	Inst Trans	1.06%	Short Ratio	3.23	Perf Half Y	-53.45%
Book/sh	22.52	P/B	2.98	EPS next Y	9.20%	ROA	-45.20%	Target Price	120.77	Perf Year	-58.44%
Cash/sh	24.71	P/C	2.72	EPS next 5Y	-	ROE	-52.20%	52W Range	32.96 - 195.99	Perf YTD	-54.24%
Dividend	-	P/FCF	-	EPS past 5Y	-21.70%	ROI	-41.30%	52W High	-64.18%	Beta	1.16
Dividend %	-	Quick Ratio	10.90	Sales past 5Y	-	Gross Margin	-	52W Low	112.99%	ATR	5.02
Employees	413	Current Ratio	10.90	Sales Q/Q	-82.50%	Oper. Margin	-	RSI (14)	63.48	Volatility	5.88% 8.25%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-27.10%	Profit Margin	-	Rel Volume	0.36	Prev Close	67.13
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 04 AMC	Payout	-	Avg Volume	1.46M	Price	70.20
Recom	2.10	SMA20	20.96%	SMA50	19.28%	SMA200	-37.00%	Volume	471,777	Change	4.57%

Jun-07-22

Upgrade

JMP Securities

Mkt Perform → Mkt Outperform

$72

May-20-22

Upgrade

Guggenheim

Neutral → Buy

$115

Feb-01-22

Upgrade

BofA Securities

Underperform → Neutral

$171 → $141

Nov-19-21

Initiated

BMO Capital Markets

Outperform

$187

Sep-23-21

Initiated

Stifel

Buy

$202

Aug-26-21

Initiated

Morgan Stanley

Equal-Weight

$160

Jun-04-21

Upgrade

Citigroup

Neutral → Buy

May-17-21

Downgrade

Oppenheimer

Outperform → Perform

May-10-21

Upgrade

Jefferies

Hold → Buy

$208 → $196

Apr-26-21

Resumed

Credit Suisse

Outperform

$285

Dec-08-20

Initiated

JMP Securities

Mkt Perform

Dec-08-20

Initiated

Evercore ISI

Outperform

Nov-17-20

Downgrade

BofA Securities

Neutral → Underperform

$196

Nov-10-20

Downgrade

Jefferies

Buy → Hold

$206 → $208

Nov-10-20

Downgrade

Guggenheim

Buy → Neutral

$230

Nov-09-20

Reiterated

H.C. Wainwright

Buy

$233 → $265

Sep-28-20

Initiated

BofA Securities

Neutral

$172

Sep-18-20

Downgrade

Citigroup

Buy → Neutral

$127 → $183

May-01-20

Upgrade

JP Morgan

Neutral → Overweight

$116

Apr-16-20

Initiated

Goldman

Buy

$151

Jun-30-22 01:08PM	Biotech ETF Tops in June: 5 Stocks That Outperform Zacks
Jun-09-22 04:40PM	Why Mirati Therapeutics Stock Is Skyrocketing This Week Motley Fool
10:43AM	The Zacks Analyst Blog Highlights Bristol Myers, Turning Point Therapeutics, Regeneron, Novavax, and Mirati Therapeutics Zacks
Jun-08-22 01:20PM	Biotech Stock Roundup: BMY's Acquisition, REGN to Buy Libtayo & More Zacks
11:45AM	Mirati (MRTX) Up on Positive Data From NSCLC Study on Adagrasib Zacks
Jun-07-22 07:21PM	Did Mirati Therapeutics Just Leapfrog Amgen? TheStreet.com +36.45%
04:04PM	The Surprising Way Mirati Therapeutics Is Angling To Rival Amgen And Could Succeed Investor's Business Daily
12:33PM	Stock Market Trades Mixed As Investors Worry About Retail Sector, U.S. Dollar; Oil Stocks Gain Investor's Business Daily
Jun-06-22 08:43AM	Mirati Therapeutics Posts Adagrasib Data In Lung Cancer Patients With CNS Metastases Benzinga
08:00AM	New Late-Breaking Data on Investigational Adagrasib Show Regression of Central Nervous System (CNS) Metastases in Patients with KRASG12C-mutated Non-Small Cell Lung Cancer (NSCLC) with Active, Untreated CNS Metastases PR Newswire
08:00AM	Mirati drug helps some patients whose lung cancer spread to the brain -study Reuters
Jun-03-22 11:31AM	Mirati (MRTX) Down 35.5% Since Last Earnings Report: Can It Rebound? Zacks +10.11%
May-29-22 08:21AM	Need To Know: The Consensus Just Cut Its Mirati Therapeutics, Inc. (NASDAQ:MRTX) Estimates For 2022 Simply Wall St.
May-27-22 04:11PM	Mirati Therapeutics Plunges As Its Hopes To Take On Amgen In Lung Cancer Crash Investor's Business Daily -31.90%
02:39PM	Mirati (MRTX) Down 23% on Mixed Data From Lung Cancer Study Zacks
09:57AM	Biotech stocks get a boost, or plunge, as new clinical data is shared before major cancer meeting MarketWatch
May-26-22 05:00PM	Mirati drug shrinks tumors in 44% of advanced lung cancer patients Reuters
05:00PM	Investigational Adagrasib Delivers Positive Results in Registration-Enabling Study of Patients with KRASG12C-Mutated Advanced Non-Small Cell Lung Cancer PR Newswire
May-25-22 04:30PM	Mirati Therapeutics to Participate in Two Upcoming Healthcare Conferences PR Newswire
May-20-22 02:17PM	Mirati (MRTX) Seeks EU Nod for Adagrasib to Treat Lung Cancer Zacks +6.27%
May-19-22 04:30PM	Mirati Therapeutics Submits Marketing Authorization Application to the European Medicines Agency for Investigational Adagrasib as a Treatment for Previously-Treated KRASG12C-mutated Non-Small Cell Lung Cancer PR Newswire
May-16-22 04:30PM	Mirati Therapeutics Appoints Laurie Stelzer as Chief Financial Officer PR Newswire
May-05-22 02:14PM	Mirati (MRTX) Q1 Loss Wider Than Expected, Sales Beat Zacks
May-04-22 04:01PM	Mirati Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Updates PR Newswire
Apr-27-22 04:30PM	Mirati Therapeutics to Present New Research at the 2022 ASCO Annual Meeting Showcasing Clinical Advances of Treating KRASG12C-Mutated Lung Cancer with Investigational Adagrasib PR Newswire
Apr-20-22 04:30PM	Mirati Therapeutics to Report First Quarter 2022 Financial Results and Recent Corporate Updates PR Newswire
Apr-06-22 03:26PM	Top 10 Stocks Billionaire Mets Owner Steve Cohen Just Added to His Portfolio Insider Monkey
Mar-30-22 11:30AM	Mirati (MRTX) Down 6% Since Last Earnings Report: Can It Rebound? Zacks
Mar-21-22 08:25AM	Is Mirati Therapeutics (MRTX) A Smart Long-Term Buy? Insider Monkey -5.24%
Mar-11-22 12:06PM	Mirati (MRTX) Focuses on Seeking Nod for KRAS Drug Adagrasib Zacks
Mar-07-22 09:00AM	10 Latest Stock Picks of Billionaire Steve Cohen Insider Monkey
Mar-02-22 04:30PM	Mirati Therapeutics to Participate in the 42nd Annual Cowen Healthcare Conference PR Newswire
Mar-01-22 07:52AM	Mirati (MRTX) Q4 Earnings and Sales Fall Short of Estimates Zacks
Feb-28-22 04:01PM	Mirati Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Updates PR Newswire
Feb-25-22 08:34AM	Is a Surprise Coming for Mirati (MRTX) This Earnings Season? Zacks
Feb-24-22 07:55AM	5 Drug/Biotech Stocks Set to Outpace Q4 Earnings Estimates Zacks
Feb-21-22 03:00PM	Mirati (MRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release Zacks
Feb-17-22 11:55AM	Mirati (MRTX) Down on Longer Review Period for Adagrasib NDA Zacks
Feb-16-22 04:13PM	Biotech Stock Values Cut in Half While Drug Setbacks Pile Up Bloomberg -12.84%
02:24PM	Why Mirati Therapeutics Stock Is Plunging Today Motley Fool
08:21AM	Mirati Therapeutics' Adagrasib Application Under FDA Review For Lung Cancer Setting Benzinga
04:40AM	What You Need To Know About The Mirati Therapeutics, Inc. (NASDAQ:MRTX) Analyst Downgrade Today Simply Wall St.
Feb-15-22 04:15PM	U.S. Food and Drug Administration (FDA) Accepts Mirati Therapeutics' New Drug Application for Adagrasib as Treatment of Previously Treated KRASG12C-Mutated Non-Small Cell Lung Cancer PR Newswire +5.83%
Feb-14-22 07:30AM	Mirati Therapeutics to Report Fourth Quarter and Full Year Financial Results for 2021 and Recent Corporate Updates on February 28, 2022 PR Newswire
Feb-07-22 09:59AM	We're Not Very Worried About Mirati Therapeutics' (NASDAQ:MRTX) Cash Burn Rate Simply Wall St.
Feb-04-22 05:05PM	Did Hedge Funds Get Mirati Therapeutics, Inc. (MRTX) Right? Insider Monkey
Feb-03-22 04:35PM	Top 10 Stock Picks of Samuel Isalys OrbiMed Advisors Insider Monkey
Feb-02-22 04:30PM	Mirati Therapeutics to Participate in Two Upcoming Healthcare Conferences PR Newswire
Feb-01-22 05:35PM	Gilead Sciences (GILD) Q4 Earnings Miss Estimates Zacks
Jan-25-22 05:38PM	Kistler-Tiffany Companies, LLC Buys Vanguard S&P 500 ETF, PowerShares QQQ Trust Ser 1, ... GuruFocus.com
Jan-21-22 01:11PM	Amgen's (AMGN) KRAS Inhibitor Gets Nod in Japan for Lung Cancer Zacks
12:14PM	Mirati Therapeutics Posts 41% Objective Response Rate In Pretreated GI Cancer Patients Benzinga
10:00AM	Mirati Therapeutics Presents Positive Clinical Data with Investigational Adagrasib in Patients with KRASG12C-Mutated Gastrointestinal Cancers PR Newswire
Jan-20-22 04:54AM	Should Investors Worry About Mirati Therapeutics Inc's Insider Sells? GuruFocus.com
Jan-14-22 02:18PM	BridgeBio (BBIO), Amgen Partner in Advanced Solid Tumors Study Zacks
08:27AM	Why Mirati Therapeutics Was Sinking This Week Motley Fool
Jan-10-22 10:19AM	Amgen's (AMGN) KRAS Inhibitor Gets Nod for Lung Cancer in EU Zacks -6.08%
Jan-04-22 04:30PM	Mirati Therapeutics to Present at the J.P. Morgan 40th Annual Virtual Healthcare Conference PR Newswire -6.08%
Dec-29-21 06:51PM	Investigation Alert: Did You Lose Money on Your Stock? Johnson Fistel, LLP Encourages Investors to Contact the Firm PR Newswire
Dec-23-21 07:38AM	MainStay VP Wellington Mid Cap Portfolio Buys Icon PLC, Digital Turbine Inc, Integra ... GuruFocus.com
Dec-13-21 11:38PM	Glenview Capital Management Buys Willis Towers Watson PLC, Uber Technologies Inc, Baxter ... GuruFocus.com
Dec-08-21 06:38PM	Inv Corp Small Cap Growth Buys Zuora Inc, Ollie's Bargain Outlet Holdings Inc, Sonic Automotive ... GuruFocus.com
Dec-07-21 04:38PM	Mutual of America VIP Small-Cap Growth Portfolio Buys Zuora Inc, Ollie's Bargain Outlet ... GuruFocus.com
03:47PM	Hedge Funds Are Dumping Mirati Therapeutics, Inc. (MRTX) Insider Monkey
Nov-23-21 04:30PM	Mirati Therapeutics to Participate in the 4th Annual Evercore ISI HealthCONx Conference PR Newswire
08:53AM	Mirati (MRTX), Verastem to Study Cancer Drugs for NSCLC Zacks
Nov-22-21 07:30AM	Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in Combination with VS-6766 in KRASG12C-Mutant Non-Small Cell Lung Cancer PR Newswire
Nov-18-21 10:13AM	Mirati (MRTX) to Begin Clinical Study in MTAP-Deleted Cancers Zacks
Nov-17-21 07:30AM	Mirati Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration of MRTX1719 to Treat MTAP-Deleted Cancers PR Newswire
Nov-15-21 11:20AM	Amgen's (AMGN) KRAS Inhibitor Gets CHMP Nod for Lung Cancer Zacks
Nov-10-21 09:11PM	Mirati Therapeutics Announces Pricing of Public Offering of Common Stock PR Newswire -11.36%
Nov-09-21 04:23PM	Mirati Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire
11:00AM	Mirati (MRTX) Beats on Q3 Earnings, Begins NDA Adagrasib Filing Zacks
09:00AM	Mirati Therapeutics to Participate in the Stifel 2021 Virtual Healthcare Conference PR Newswire
Nov-08-21 05:25PM	Mirati (MRTX) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:01PM	Mirati Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Updates PR Newswire
12:44PM	Is Mirati Therapeutics (MRTX) A Smart Long-Term Buy? Insider Monkey
Nov-05-21 05:15PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mirati Therapeutics, Inc. - MRTX ACCESSWIRE
Nov-04-21 04:41AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mirati Therapeutics, Inc. - MRTX PR Newswire
Nov-02-21 08:47AM	(MRTX) Alert: Did You Lose Money on Your Mirati Therapeutics Investment? Contact Johnson Fistel Regarding Investigation PR Newswire
Nov-01-21 04:30PM	Mirati Therapeutics to Report Financial Results for Third Quarter 2021 and Recent Corporate Updates on November 8, 2021 PR Newswire -13.57%
02:33PM	Mid-Afternoon Market Update: loanDepot Surges After Q3 Results; Mirati Therapeutics Shares Slide Benzinga
02:30PM	Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Mirati Therapeutics, Inc. (MRTX) Investigation ACCESSWIRE
02:05PM	(MRTX) Alert: Did You Lose Money on Your Mirati Therapeutics Investment? Contact Johnson Fistel Regarding Investigation GlobeNewswire
12:47PM	Was The Smart Money Right About Mirati Therapeutics, Inc. (MRTX)? Insider Monkey
Oct-27-21 03:03PM	Earnings Preview: Mirati (MRTX) Q3 Earnings Expected to Decline Zacks
Oct-07-21 04:30PM	Mirati Therapeutics to Collaborate with Sanofi on Phase 1/2 Study Evaluating Combination of adagrasib with a SHP2 Inhibitor in KRAS G12C-mutated Lung Cancer PR Newswire
Oct-04-21 04:30PM	Mirati Therapeutics to Present New Research From its Innovative Oncology Pipeline at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer PR Newswire
01:59PM	Hedge Funds Are Selling Mirati Therapeutics, Inc. (MRTX) Insider Monkey
Sep-24-21 04:15PM	Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) PR Newswire
Sep-20-21 04:09PM	Why Mirati Therapeutics Is A Dangerous Rival To Amgen In Colon Cancer Investor's Business Daily
12:09PM	Why Mirati Therapeutics Stock Is Trading Higher Today Benzinga
11:44AM	Mirati (MRTX) Reports Positive Data From Colorectal Cancer Study Zacks
09:45AM	New CEO At Mirati Therapeutics Benzinga
09:38AM	Mirati Unveils Long-term Survival Data For Sitravatinib/Nivolumab Combo In Lung Cancer Patients Benzinga
09:19AM	Mirati Posts Adagrasib Data In KRAS-Mutated Lung Cancer, FDA Filing Now On The Cards Benzinga
09:12AM	Mirati Showcases New KRAS Drug Data In Colorectal Cancer At ESMO Benzinga
08:20AM	Mirati Therapeutics Announces Long-term Survival Results from an Exploratory Analysis of Sitravatinib plus Nivolumab in Patients with Non-squamous Non-Small Cell Lung Cancer Who are Resistant to Checkpoint Inhibitors PR Newswire
07:55AM	Mirati Therapeutics taps industry veteran Meek as CEO Reuters
07:55AM	Mirati Therapeutics Appoints David Meek as Chief Executive Officer PR Newswire

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Christensen Jamie	EVP, Chief Scientific Officer	May 23	Sale	63.54	624	39,649	86,804	Jun 14 04:35 PM
Cherrington Julie M	Director	Jan 19	Sale	116.07	1,475	171,203	2,546	Jan 20 04:57 PM
BAUM CHARLES M	President,Founder,Head of R&D	Jan 18	Option Exercise	27.00	3,703	99,981	130,416	Jan 18 08:32 PM
REED VICKIE S	SVP, Chief Accounting Officer	Jan 18	Sale	120.48	533	64,217	15,369	Jan 18 08:34 PM
Hickey Benjamin	EVP, Chief Commercial Officer	Jan 18	Sale	120.48	627	75,543	34,976	Jan 18 08:32 PM
BAUM CHARLES M	President,Founder,Head of R&D	Jan 18	Sale	120.48	2,517	303,253	127,899	Jan 18 08:32 PM
Christensen Jamie	EVP, Chief Scientific Officer	Jan 18	Sale	120.51	627	75,558	87,428	Jan 18 08:33 PM
Hickey Benjamin	EVP, Chief Commercial Officer	Jan 07	Sale	135.94	1,964	266,984	24,848	Jan 07 08:27 PM
REED VICKIE S	SVP, Chief Accounting Officer	Jan 07	Sale	135.94	345	46,900	10,525	Jan 07 08:26 PM
BAUM CHARLES M	President,Founder,Head of R&D	Jan 04	Sale	147.75	4,114	607,855	101,170	Jan 06 04:51 PM
REED VICKIE S	SVP, Chief Accounting Officer	Jan 04	Sale	147.74	758	111,987	10,870	Jan 06 04:50 PM
Christensen Jamie	EVP, Chief Scientific Officer	Jan 04	Sale	147.72	1,442	213,017	77,300	Jan 06 04:51 PM
Christensen Jamie	EVP, Chief Scientific Officer	Dec 06	Sale	130.79	1,201	157,078	59,505	Dec 07 05:52 PM
BAUM CHARLES M	President & Head of R&D	Dec 03	Option Exercise	8.49	47,204	400,762	159,918	Dec 03 08:09 PM
BAUM CHARLES M	President & Head of R&D	Dec 03	Sale	133.20	47,204	6,287,687	112,714	Dec 03 08:09 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience